Home » Topics » BioWorld Science

BioWorld Science
RSS

Beijing Tide Pharmaceutical synthesizes AGTR2 antagonists

Oct. 10, 2019

Roche divulges new MGL inhibitors

Oct. 10, 2019

Chinese investigators patent ROCK inhibitors

Oct. 10, 2019

RCC2 as a novel therapeutic target in glioblastoma

Oct. 10, 2019

Results from OS analysis of KATE2 study of atezolizumab plus T-DM1 in HER2+ advanced BC

Oct. 10, 2019

Improved gamma-gamma cross-linking could hep prevent thromboembolic diseases

Oct. 10, 2019

Novel bispecific antibody 4224 shows in vivo efficacy in tumors expressing high levels of EpCAM

Oct. 10, 2019

Topline results presented for phase Ib study of ANX-007 in patients with glaucoma

Oct. 10, 2019

Mithra initiates phase III E4 Comfort clinical program for Donesta

Oct. 10, 2019

First patient enrolled in phase II study of bavituximab plus pembrolizumab in gastric cancer

Oct. 10, 2019

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...